Pregledni rad
https://doi.org/10.20471/sept.2026.62.02.06
Comparative Evaluation of Donanemab and Lecanemab in Early Alzheimer’s Disease: A Clinical Practice-Oriented Narrative Review
Kuan Yu Chu
; Stomatološki fakultet i Poslijediplomski institut za dentalne znanosti, Fakultet oralne medicine, Nacionalno obrambeno medicinsko sveučilište, Taipei, Tajvan Odjel za zdravstvo i socijalnu skrb, Sveučilište u Taipeiju, Taipei, Tajvan
Sažetak
Aim: The regulatory approval of donanemab (Kisunla) and lecanemab (Leqembi) represents a pivotal moment in Alzheimer's disease therapeutics, offering the first treatments that demonstrate meaningful clinical benefits while targeting underlying amyloid pathology. This narrative review provides a comprehensive clinical comparison of these novel anti-amyloid monoclonal antibodies to guide clinical practice decisions. Materials and Methods: This narrative review analyzes available clinical evidence on donanemab and lecanemab, focusing on treatment efficacy, amyloid clearance, safety profiles, and factors relevant to clinical implementation. Results: Both treatments demonstrate statistically significant slowing of cognitive decline in early Alzheimer's disease, with donanemab showing 35 % slowing in the low-medium tau population (CDR-SB: -1.86 vs placebo -2.42, p < 0.001, TRAILBLAZER-ALZ 2 study, 18 months) and lecanemab demonstrating 27 % slowing on clinical rating scales (CDR-SB: -1.21 vs placebo -1.66, p < 0.001, CLARITY-AD study, 18 months). Donanemab achieves greater amyloid clearance (84 % reduction at 18 months) compared with lecanemab (68 % reduction at 18 months), potentially allowing for treatment discontinuation after achieving adequate clearance. However, donanemab carries higher rates of amyloid-related imaging abnormalities (ARIA), with ARIA-E occurring in 24 % versus 12.6 % for lecanemab. Clinical implementation requires careful patient selection based on APOE ε4 status, baseline imaging findings, and tau burden assessment. Conclusion: This review presents evidence-based decision algorithms for treatment selection, comprehensive ARIA monitoring protocols, and practical implementation strategies. The choice between these therapies should be individualized considering patient-specific risk factors, infrastructure requirements, and cost-effectiveness considerations. While both represent significant therapeutic advances, their modest clinical benefits and safety considerations necessitate judicious patient selection and specialized monitoring capabilities.
Ključne riječi
onoclonal antibodies; amyloid beta-peptides; apolipoprotein E; cognitive dysfunction
Hrčak ID:
352588
URI
Datum izdavanja:
16.10.2026.
Posjeta: 0 *